This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Jun;13(6):734-5; author reply 736-7.

doi: 10.1634/theoncologist.2008-0063.

18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma

Ester J M Siemerink, Nanno H Mulder, Adrienne H Brouwers, Geke A P Hospers

PMID: 18586929
DOI: 10.1634/theoncologist.2008-0063

Free article

Comment

18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma

Ester J M Siemerink et al. Oncologist. 2008 Jun.

Free article

. 2008 Jun;13(6):734-5; author reply 736-7.

doi: 10.1634/theoncologist.2008-0063.

Authors

Ester J M Siemerink, Nanno H Mulder, Adrienne H Brouwers, Geke A P Hospers

PMID: 18586929
DOI: 10.1634/theoncologist.2008-0063

No abstract available

PubMed Disclaimer

Comment on

Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
O'Neil BH, Venook AP. O'Neil BH, et al. Oncologist. 2007 Dec;12(12):1425-32. doi: 10.1634/theoncologist.12-12-1425. Oncologist. 2007. PMID: 18165619 Review.

Similar articles

Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Lee JH, Park JY, Kim DY, Ahn SH, Han KH, Seo HJ, Lee JD, Choi HJ. Lee JH, et al. Liver Int. 2011 Sep;31(8):1144-9. doi: 10.1111/j.1478-3231.2011.02541.x. Epub 2011 May 3. Liver Int. 2011. PMID: 21745288
Sorafenib in hepatocellular carcinoma.
Josephs DH, Ross PJ. Josephs DH, et al. Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. doi: 10.12968/hmed.2010.71.8.77669. Br J Hosp Med (Lond). 2010. PMID: 20852487 Review.
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Reig M, Matilla A, Bustamante J, Castells L, de La Mata M, Delgado M, Moreno JM, Forner A, Varela M. Reig M, et al. Gastroenterol Hepatol. 2010 Dec;33(10):741-52. doi: 10.1016/j.gastrohep.2010.05.007. Epub 2010 Sep 18. Gastroenterol Hepatol. 2010. PMID: 20851505 Spanish. No abstract available.
Sorafenib in advanced hepatocellular carcinoma.
Palmer DH. Palmer DH. N Engl J Med. 2008 Dec 4;359(23):2498; author reply 2498-9. N Engl J Med. 2008. PMID: 19065750 No abstract available.
Sorafenib: where do we go from here?
Siegel AB, Olsen SK, Magun A, Brown RS Jr. Siegel AB, et al. Hepatology. 2010 Jul;52(1):360-9. doi: 10.1002/hep.23633. Hepatology. 2010. PMID: 20578152 Free PMC article. Review.

See all similar articles

Cited by

Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging.
Bouattour M, Payancé A, Wassermann J. Bouattour M, et al. World J Hepatol. 2015 Sep 18;7(20):2245-63. doi: 10.4254/wjh.v7.i20.2245. World J Hepatol. 2015. PMID: 26380650 Free PMC article. Review.
Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P. Pazo-Cid RA, et al. Clin Transl Oncol. 2012 Aug;14(8):564-74. doi: 10.1007/s12094-012-0842-y. Epub 2012 Jul 18. Clin Transl Oncol. 2012. PMID: 22855137
(18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma.
Simoneau E, Hassanain M, Madkhali A, Salman A, Nudo CG, Chaudhury P, Metrakos P. Simoneau E, et al. Curr Oncol. 2014 Aug;21(4):e551-6. doi: 10.3747/co.21.1959. Curr Oncol. 2014. PMID: 25089106 Free PMC article.
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Quintela-Fandino M, Le Tourneau C, Duran I, Chen EX, Wang L, Tsao M, Bandarchi-Chamkhaleh B, Pham NA, Do T, MacLean M, Nayyar R, Tusche MW, Metser U, Wright JJ, Mak TW, Siu LL. Quintela-Fandino M, et al. Mol Cancer Ther. 2010 Mar;9(3):751-60. doi: 10.1158/1535-7163.MCT-09-0868. Epub 2010 Mar 2. Mol Cancer Ther. 2010. PMID: 20197396 Free PMC article. Clinical Trial.
Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research.
Mancini M, Summers P, Faita F, Brunetto MR, Callea F, De Nicola A, Di Lascio N, Farinati F, Gastaldelli A, Gridelli B, Mirabelli P, Neri E, Salvadori PA, Rebelos E, Tiribelli C, Valenti L, Salvatore M, Bonino F. Mancini M, et al. World J Hepatol. 2018 Feb 27;10(2):231-245. doi: 10.4254/wjh.v10.i2.231. World J Hepatol. 2018. PMID: 29527259 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Medical
- MedlinePlus Health Information